ANTIVIRAL THERAPY
metrics 2024
Pioneering insights in infectious disease management.
Introduction
ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
FUNDAMENTAL & CLINICAL PHARMACOLOGY
Elevating the standards of pharmacological research and clinical application.FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.
ARCHIVES OF VIROLOGY
Pioneering insights into virology's challenges.Archives of Virology is a prestigious academic journal dedicated to the field of virology, published by Springer Wien. Established in 1975, this journal has been a crucial platform for disseminating innovative research findings and advancements in the understanding of viral diseases and their impact on human health. It holds a notable position in the academic landscape, with a 2023 impact factor placing it in Q2 within the field of Medicine (miscellaneous) and Q3 in Virology. Its Scopus ranking within the Virology category further underscores its relevance, with a notable percentile of 45th. Although it does not provide Open Access options, the journal's rigorous peer-review process ensures the highest quality of published work, making it an essential resource for researchers, professionals, and students aiming to stay updated in the rapidly evolving field of virology. For those committed to advancing their understanding of viruses and viral diseases, Archives of Virology is a vital scholarly resource.
Journal of Clinical Virology Plus
Advancing understanding in virology and infectious diseases.The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.
JOURNAL DE MYCOLOGIE MEDICALE
Unveiling Insights into Mycological ChallengesJOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.
Hepatitis Monthly
Empowering healthcare through cutting-edge research.Hepatitis Monthly, published by BRIEFLAND in the Netherlands, is a pivotal journal in the fields of hepatology and infectious diseases. Established in 2007, it continues to make significant contributions to the understanding and management of hepatitis and related viral infections with a publication timeline extending through to 2024. Aiming to disseminate high-quality research, the journal serves as a forum for groundbreaking studies and innovations essential for healthcare professionals, researchers, and students alike. While it currently holds Q4 rankings in both hepatology and infectious disease categories, its ongoing commitment to addressing pressing health issues makes it an important resource in the academic community. Although it operates under a traditional access model, Hepatitis Monthly not only publishes original research articles, reviews, and case studies but also encourages the exchange of knowledge that helps shape future research directions and clinical practices. As it continues to explore the complexities surrounding viral hepatitis, this journal invites researchers to contribute to its mission of advancing scientific understanding and improving patient care.
Journal of Virus Eradication
Empowering research for a virus-free future.Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.
Infectious Diseases and Therapy
Advancing global health through groundbreaking research.Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.
Rheumatology and Therapy
Advancing knowledge in rheumatology and immunology.Rheumatology and Therapy, published by Springer, stands as a prominent open-access journal within the fields of Immunology and Allergy and Rheumatology. Since its inception in 2014, the journal has made significant contributions to advancing the understanding, diagnosis, and treatment of rheumatic diseases, garnering a solid reputation with an impact factor that reflects its rigorous peer-review process and scholarly influence. Currently ranked in the Q2 quartile for both its categories according to 2023 metrics, it occupies a significant position among its peers, standing at Rank #21 out of 73 in Medicine Rheumatology and Rank #101 out of 233 for Medicine Immunology and Allergy. The journal's scope encompasses cutting-edge research, reviews, and clinical studies that aim to bridge the gap between laboratory findings and patient care, making it an invaluable resource for researchers, clinicians, and students alike. With its commitment to open access, Rheumatology and Therapy ensures that high-quality research is available to a global audience, fostering collaboration and innovation in rheumatology and immunology. To learn more, visit their official site and explore the wealth of knowledge available.
INVESTIGATIONAL NEW DRUGS
Driving Discoveries in Oncology and PharmacologyINVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.
INFECTION
Shaping the Future of Infectious Disease ResearchINFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.